Abeona Therapeutics' Gene Therapy for X-linked Retinoschisis Joins FDA's Rare Disease Pilot Program, Offering Hope for IRD Community

Abeona Therapeutics' Gene Therapy for X-linked Retinoschisis Joins FDA's Rare Disease Pilot Program, Offering Hope for IRD Community

Cleveland, OH – The inherited retinal disease (IRD) community has received encouraging news as Abeona Therapeutics' investigational gene therapy, ABO-503, designed to treat X-linked retinoschisis (XLRS), has been selected for the U.S. Food and Drug Administration's (FDA) Rare Disease Endpoint Advancement (RDEA) Pilot Program. This significant development, announced on October 13, 2025, by Ophthalmology Times Europe, is poised to accelerate the development of new treatments for rare diseases like XLRS, which could have broader implications for other IRDs.

XLRS is a rare, monogenic retinal disease caused by mutations in the RS1 protein, leading to irreversible photoreceptor cell loss and severe visual impairment. The inclusion of ABO-503 in this competitive FDA program is a testament to the urgent need for therapies in this underserved area.

What the RDEA Pilot Program Means for the IRD Community

The FDA's RDEA Pilot Program was established to support the development of novel efficacy endpoints for drugs treating rare diseases. For rare conditions such as IRDs, traditional clinical trial designs and established endpoints may not always be practical due to small patient populations and limited natural history data. The RDEA program aims to address these challenges by providing sponsors, like Abeona Therapeutics, with structured opportunities for enhanced communication and collaboration with the FDA.

This enhanced engagement includes frequent advice and regular ad-hoc conversations, which can significantly accelerate the development and validation of product-specific novel efficacy endpoints. The program runs from 2023 through September 30, 2027, accepting a maximum of three proposals per year. By fostering this close collaboration, the FDA seeks to advance rare disease drug development and promote innovation in science.

ABO-503: A Closer Look

ABO-503 is an adeno-associated virus (AAV) gene therapy that delivers a functional human RS1 gene, packaged in a proprietary AIM™ capsid AAV204. Preclinical studies have shown promising results, demonstrating structural and functional improvements in a mouse model of XLRS. These improvements include increased cone photoreceptor density, restoration of outer retina architecture by eliminating XLRS-characteristic cysts, and better visual function as measured by electroretinogram (ERG). Abeona Therapeutics anticipates completing investigational new drug (IND)-enabling studies in the second half of 2026.

Vish Seshadri, CEO of Abeona, expressed optimism that participation in the RDEA program will improve the success rate of their XLRS clinical development efforts. He also noted that it could facilitate pipeline innovation by using novel efficacy endpoints in the development of new therapies across other inherited retinal diseases.

Looking Ahead

The selection of ABO-503 into the RDEA Pilot Program represents a crucial step forward for the XLRS community and potentially for other IRDs. This collaboration between Abeona Therapeutics and the FDA aims to streamline the path for new treatments by addressing the unique challenges of rare disease research. The learnings from this program are also intended to be shared more broadly through FDA presentations, guidance documents, and workshops, benefiting the wider rare disease community.